Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640704 | 0.90 | NOTUM (0.40) | NOTUMLMNAMAPTKDM4EPOLB | |
| SCHEMBL13641040 | 0.88 | NOTUM (0.53) | NOTUMLMNAMAPTPOLBDRD2 | |
| SCHEMBL13641030 | 0.88 | NOTUM (0.39) | NOTUMDRD2 | |
| SCHEMBL13640820 | 0.86 | SETD2 (0.39) | NOTUMLMNAMAPTKCNH2GRIN2B | |
| SCHEMBL13640829 | 0.81 | SIGMAR1 (0.49) | SLC18A3SIGMAR1LMNAMAPTOPRL1 | |
| SCHEMBL12084247 | 0.81 | NOTUM (0.54) | NOTUMKCNH2 | |
| SCHEMBL13640862 | 0.80 | MEN1 (0.39) | KDM4EDRD2 | |
| SCHEMBL13000373 | 0.80 | NOTUM (0.56) | NOTUMKCNH2POLB | |
| SCHEMBL13640752 | 0.80 | MAPT (0.41) | LMNAMAPTOPRL1KCNH2GRIN2B | |
| SCHEMBL13640880 | 0.80 | CTSS (0.37) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | NOTUM 2979/4885SLC18A3 319/4885SIGMAR1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.